- Home
- CCBG vs RIGL Comparison
CCBG vs RIGL Comparison
Compare CCBG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCBG | RIGL |
|---|---|---|
| Founded | 1895 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 828.1M | 911.8M |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CCBG | RIGL |
|---|---|---|
| Price | $51.05 | $51.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $51.83 | ★ $63.00 |
| AVG Volume (30 Days) | 68.0K | ★ 191.7K |
| Earning Date | 10-20-2026 | 11-10-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | 15.38 | ★ 1867.68 |
| EPS | 0.92 | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $1.18 | $3.89 |
| Revenue Next Year | $3.29 | $21.95 |
| P/E Ratio | $55.17 | ★ $38.37 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $38.55 | $24.84 |
| 52 Week High | $53.60 | $52.24 |
Technical Indicators
Market Signals| Indicator | CCBG | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 61.01 | 64.49 |
| Support Level | $47.63 | $44.83 |
| Resistance Level | $51.04 | N/A |
| Average True Range (ATR) | 0.95 | 1.48 |
| MACD | 0.30 | 0.30 |
| Stochastic Oscillator | 82.13 | 94.44 |
Price Performance
Historical ComparisonAbout CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.